Polymorphisms in the mTOR Gene and Risk of Sporadic Prostate Cancer in an Eastern Chinese Population

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Li, Qiaoxin ^a,b   Gu, Chengyuan ^a,b   Zhu, Yao ^a,b   Wang, Mengyun ^a,b   Yang, Yajun ^b,c   Wang, Jiucun ^b,c   Jin, Li ^b,c   Zhu, Mei Ling ^a,b   Shi, Ting Yan ^a,b   He, Jing ^a,b   Zhou, Xiaoyan ^b   Ye, Ding wei ^a,b   Wei, Qingyi ^a,d  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

^c Fudan Taizhou Institute of Health Sciences   (China)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; MAMMALIAN TARGET OF RAPAMYCIN; PROSTATE SPECIFIC ANTIGEN;

AGE; AGED; ARTICLE; BODY MASS; CANCER RISK; CANCER STAGING; CASE CONTROL STUDY; CHINESE; COMPARATIVE STUDY; CONTROLLED STUDY; GENE FREQUENCY; GENE LOCUS; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC MODEL; GENOTYPE ENVIRONMENT INTERACTION; GLEASON SCORE; HAPLOTYPE; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MAMMALIAN TARGET OF RAPAMYCIN GENE; OBESITY; PREDICTIVE VALUE; PROSTATE CANCER; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING HABIT; WILD TYPE;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; CHINA; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; RISK; TOR SERINE-THREONINE KINASES;

EID: 84881095969     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0071968     Document Type: Article

References (38)

1. Jemal A, Bray F, (2011) Center MM, Ferlay J, Ward E, et al (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
2. Matsuda T, Saika K, (2009) Comparison of time trends in prostate cancer incidence (1973-2002) in Asia, from cancer incidence in five continents, Vols IV-IX. Jpn J Clin Oncol 39: 468-469.
3. Gudmundsson J, Sulem P, Manolescu A, Amundadottir LT, Gudbjartsson D, et al. (2007) Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet 39: 631-637.
4. Thomas G, Jacobs KB, Yeager M, Kraft P, Wacholder S, et al. (2008) Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet 40: 310-315.
5. Eeles RA, Kote-Jarai Z, Al OA, Giles GG, Guy M, et al. (2009) Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat Genet 41: 1116-1121.
6. Stadler ZK, Vijai J, Thom P, Kirchhoff T, Hansen NA, et al. (2010) Genome-wide association studies of cancer predisposition. Hematol Oncol Clin North Am 24: 973-996.
7. Moore T, Beltran L, Carbajal S, Strom S, Traag J, et al. (2008) Dietary energy balance modulates signaling through the Akt/mammalian target of rapamycin pathways in multiple epithelial tissues. Cancer Prev Res (Phila) 1: 65-76.
8. Vivanco I, Sawyers CL, (2002) The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2: 489-501.
9. Yang Q, Guan KL, (2007) Expanding mTOR signaling. Cell Res 17: 666-681.
10. Fingar DC, Richardson CJ, Tee AR, Cheatham L, Tsou C, et al. (2004) mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Mol Cell Biol 24: 200-216.
11. Edinger AL, Thompson CB, (2002) Akt maintains cell size and survival by increasing mTOR-dependent nutrient uptake. Mol Biol Cell 13: 2276-2288.
12. Patel PH, Chadalavada RS, Chaganti RS, Motzer RJ, (2006) Targeting von Hippel-Lindau pathway in renal cell carcinoma. Clin Cancer Res 12: 7215-7220.
13. Zhou H, Huang S, (2010) The complexes of mammalian target of rapamycin. Curr Protein Pept Sci 11: 409-424.
14. Hidalgo M, Rowinsky EK, (2000) The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene 19: 6680-6686.
15. Sato T, Nakashima A, Guo L, Coffman K, Tamanoi F, (2010) Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer. Oncogene 29: 2746-2752.
16. Ohori M, Wheeler TM, Scardino PT, (1994) The New American Joint Committee on Cancer and International Union Against Cancer TNM classification of prostate cancer. Clinicopathologic correlations. Cancer 74: 104-114.
17. He J, Qiu LX, Wang MY, Hua RX, Zhang RX, et al. (2012) Polymorphisms in the XPG gene and risk of gastric cancer in Chinese populations. Hum Genet 131: 1235-1244.
18. Hahn LW, Ritchie MD, Moore JH, (2003) Multifactor dimensionality reduction software for detecting gene-gene and gene-environment interactions. Bioinformatics 19: 376-382.
19. Ritchie MD, Hahn LW, Roodi N, Bailey LR, Dupont WD, et al. (2001) Multifactor-dimensionality reduction reveals high-order interactions among estrogen-metabolism genes in sporadic breast cancer. Am J Hum Genet 69: 138-147.
20. Wacholder S, Chanock S, Garcia-Closas M, El GL, Rothman N, (2004) Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst 96: 434-442.
21. Guertin DA, Sabatini DM, (2005) An expanding role for mTOR in cancer. Trends Mol Med 11: 353-361.
22. Sarbassov DD, Ali SM, Sabatini DM, (2005) Growing roles for the mTOR pathway. Curr Opin Cell Biol 17: 596-603.
23. Wullschleger S, Loewith R, Hall MN, (2006) TOR signaling in growth and metabolism. Cell 124: 471-484.
24. Chen J, Shao P, Cao Q, Li P, Li J, et al. (2012) Genetic variations in a PTEN/AKT/mTOR axis and prostate cancer risk in a Chinese population. PLoS One 7: e40817.
25. Xu M, Tao G, Kang M, Gao Y, Zhu H, et al. (2013) A polymorphism (rs2295080) in mTOR promoter region and its association with gastric cancer in a Chinese population. PLoS One 8: e60080.
26. Cao Q, Ju X, Li P, Meng X, Shao P, et al. (2012) A functional variant in the MTOR promoter modulates its expression and is associated with renal cell cancer risk. PLoS One 7: e50302.
27. Hildebrandt MA, Yang H, Hung MC, Izzo JG, Huang M, et al. (2009) Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy. J Clin Oncol 27: 857-871.
28. Huang L, Huang J, Wu P, Li Q, Rong L, et al. (2012) Association of genetic variations in mTOR with risk of childhood acute lymphoblastic leukemia in a Chinese population. Leuk Lymphoma 53: 947-951.
29. He J, Wang MY, Qiu LX, Zhu ML, Shi TY, et al. (2013) Genetic variations of mTORC1 genes and risk of gastric cancer in an Eastern Chinese population. Mol Carcinog.
30. Zhu ML, Yu H, Shi TY, He J, Wang MY, et al. (2013) Polymorphisms in mTORC1 Genes Modulate Risk of Esophageal Squamous Cell Carcinoma in Eastern Chinese Populations. J Thorac Oncol 8: 788-795.
31. Tokuhiro S, Yamada R, Chang X, Suzuki A, Kochi Y, et al. (2003) An intronic SNP in a RUNX1 binding site of SLC22A4, encoding an organic cation transporter, is associated with rheumatoid arthritis. Nat Genet 35: 341-348.
32. Buratti E, Brindisi A, Pagani F, Baralle FE, (2004) Nuclear factor TDP-43 binds to the polymorphic TG repeats in CFTR intron 8 and causes skipping of exon 9: a functional link with disease penetrance. Am J Hum Genet 74: 1322-1325.
33. Naukkarinen J, Gentile M, Soro-Paavonen A, Saarela J, Koistinen HA, et al. (2005) USF1 and dyslipidemias: converging evidence for a functional intronic variant. Hum Mol Genet 14: 2595-2605.
34. Liu L, Wu C, Wang Y, Zhong R, Wang F, et al. (2011) Association of candidate genetic variations with gastric cardia adenocarcinoma in Chinese population: a multiple interaction analysis. Carcinogenesis 32: 336-342.
35. Zhong R, Liu L, Zou L, Sheng W, Zhu B, et al. (2013) Genetic variations in the TGFbeta signaling pathway, smoking and risk of colorectal cancer in a Chinese population. Carcinogenesis 34: 936-942.
36. Zhang XM, Zhong R, Liu L, Wang Y, Yuan JX, et al. (2011) Smoking and COX-2 functional polymorphisms interact to increase the risk of gastric cardia adenocarcinoma in Chinese population. PLoS One 6: e21894.
37. Zhang X, Zhong R, Zhang Z, Yuan J, Liu L, et al. (2011) Interaction of cyclooxygenase-2 promoter polymorphisms with Helicobacter pylori infection and risk of gastric cancer. Mol Carcinog 50: 876-883.
38. Freeman MR, Solomon KR, (2004) Cholesterol and prostate cancer. J Cell Biochem 91: 54-69.